This article is neither scaremongering nor advocacy. It's an objective guide to how corticosteroids work, when they're the right choice, how to use them safely — and when it makes sense to start looking for an alternative.
Why corticosteroids work (and why doctors prescribe them)
Topical corticosteroids — ointments, creams, and lotions containing corticosteroids — have been the foundation of inflammatory skin disease treatment for over 60 years. The 2025 American Academy of Dermatology (AAD) guidelines designate them as first-line treatment for atopic dermatitis, based on more than 100 randomized clinical trials.
How do they work? Corticosteroids suppress the local inflammatory response — they reduce pro-inflammatory cytokine production, constrict blood vessels (which is why redness fades), and calm the immune reaction in the skin. The result: less redness, less itching, less swelling. The skin gets a chance to heal.
When used short-term at the right potency and in the right location, corticosteroids are safe and highly effective. This is important to emphasize because so-called "steroid phobia" — an exaggerated fear of corticosteroids — can lead people to undertreating their eczema, which sometimes causes more harm than a correctly used corticosteroid.
How to use corticosteroids correctly: basic rules
Most problems with corticosteroids don't arise because they're a bad medication — they arise because they're not used correctly. Here are the key rules:
The right potency in the right place
Corticosteroids are divided into four potency classes (in European classification I–IV, from weakest to strongest). The face, eyelids, neck, genitals, and skin folds — these are areas with thin skin where absorption is many times higher. Only mild corticosteroids (Class I) should be used on these areas, and only short-term. Strong and very strong preparations (Class III–IV) are intended for more resilient areas like the palms, soles, or limbs.
The right amount: the fingertip unit rule
How much product to apply? Dermatologists use the fingertip unit (FTU) concept — a strip of cream from the fingertip to the first joint. One FTU covers roughly the area of one adult palm. An entire adult arm requires approximately 3 FTUs. The face and neck need 2.5 FTUs. Too little means insufficient effect; too much increases the risk of side effects.
The right duration of application
Golden rule: corticosteroids are for flares, not for maintenance. A typical course lasts 7–14 days for mild eczema, up to 2–4 weeks for more severe cases. After the skin calms down, treatment should transition to a maintenance phase — emollients and potentially non-steroidal anti-inflammatory products. Strong corticosteroids (Class III–IV) should not be used continuously for more than 14–20 days.
Proactive therapy: the "weekend" strategy
The modern approach to eczema includes so-called proactive therapy — after managing an acute flare, the corticosteroid is applied just twice a week to areas where eczema repeatedly returns. This approach has been proven to reduce flare frequency and overall corticosteroid consumption.
Tachyphylaxis: why corticosteroids stop working
One of the most frustrating phenomena for patients: a corticosteroid that once worked brilliantly gradually loses its effect. This phenomenon is called tachyphylaxis.
With long-term continuous use, the skin "gets used to" the corticosteroid — the number of corticosteroid receptors in skin cells decreases, and drug metabolism in the skin changes. The result: the same potency is no longer enough. The patient switches to a stronger product, then an even stronger one — an escalation spiral develops, which can ultimately lead to withdrawal syndrome (TSW).
The solution to tachyphylaxis is paradoxically simple: interrupt continuous use. Proactive therapy (application twice weekly) or alternating with non-steroidal products prevents tachyphylaxis. That's why it's so important to use corticosteroids "in courses," not as permanent maintenance.
Side effects: what's at risk with improper or long-term use
With short-term correct use, corticosteroid side effects are rare. Problems occur with long-term, too-frequent, or too-potent use — especially on sensitive areas.
- Skin atrophy — thinning of the skin, which becomes translucent and fragile. Blood vessels show through, the skin cracks easily and heals poorly. Most common on the face, wrists, and skin folds.
- Stretch marks (striae distensae) — tears in deeper skin layers. They resemble pregnancy stretch marks. They are irreversible.
- Telangiectasia — permanently dilated small blood vessels visible under the skin, especially on the face.
- Perioral dermatitis — a rash around the mouth, nose, and eyes, typically associated with corticosteroid use on the face.
- Steroid acne and rosacea — worsening or development of acne and rosacea at application sites.
- Rebound effect — after discontinuation, symptoms return in worse form than at the beginning. The skin enters a vicious cycle: corticosteroids → improvement → discontinuation → worsening → corticosteroids again.
- Contact allergy — a lesser-known problem: the skin may develop an allergy to the corticosteroid itself or to excipients in the product. This manifests as the product ceasing to work or the condition worsening.
- Systemic effects — when used on large areas, under occlusion, or in children, systemic absorption can occur. The consequence may be suppression of the hypothalamic-pituitary-adrenal (HPA) axis.
Important context: Most of these effects occur with long-term use of potent corticosteroids on sensitive areas. Short-term use of a mild corticosteroid on the body carries minimal risk. Undertreated eczema — with its chronic inflammation, sleep disturbances, and infection risk — can be worse for health than properly managed corticosteroid treatment.
Seven signals it's time to discuss an alternative
Corticosteroids are an excellent first-aid tool — but they're not the only option. The following situations suggest it's wise to discuss non-steroidal alternatives with your doctor:
- You've been using corticosteroids for more than 4 weeks continuously — especially on the face, neck, or skin folds.
- You need increasingly stronger products for the same effect — a classic sign of tachyphylaxis.
- Eczema returns faster and more severely after discontinuation — a possible rebound effect.
- The skin at the application site has thinned, blood vessels are showing through, or stretch marks have appeared.
- Symptoms are spreading beyond the application area — burning, redness, or peeling in areas where you never applied corticosteroids (a possible sign of TSW).
- You're concerned about children's skin — children have thinner skin and a higher surface-to-weight ratio, which increases systemic absorption.
- You want to reduce overall corticosteroid burden — even if they're still working, you're looking for a steroid-sparing strategy for the long-term maintenance phase.
What alternatives to corticosteroids exist today
Good news: the range of non-steroidal options has expanded significantly in recent years. Dermatology is moving toward so-called steroid-sparing strategies — reducing dependence on corticosteroids while maintaining eczema control.
Calcineurin inhibitors (tacrolimus, pimecrolimus)
Prescription products like Protopic® (tacrolimus) and Elidel® (pimecrolimus) suppress inflammation via a different pathway than corticosteroids — they block the protein calcineurin in T-cells. The key advantage: they don't cause skin atrophy, making them particularly suitable for sensitive areas — the face, neck, eyelids, skin folds, and genitals. They can be used both for flare treatment and as maintenance therapy.
PDE4 inhibitors (crisaborole)
Crisaborole (Eucrisa®) blocks the enzyme phosphodiesterase 4 (PDE4) and reduces inflammation in and beneath the skin. Approved for mild to moderate eczema, it can be used long-term. Non-steroidal, with no risk of skin atrophy.
JAK inhibitors
The newest class of non-steroidal products. They block the JAK-STAT signaling pathway, which transmits pro-inflammatory cytokine signals. Ruxolitinib (Opzelura®) is available as a cream — approved since September 2025 for children as young as 2 years old. It represents a revolution in topical non-steroidal treatment.
Biologic therapy
For moderate to severe eczema that doesn't respond to topical treatment, injectable biologics are available — dupilumab (Dupixent®), tralokinumab (Adtralza®), lebrikizumab (Ebglyss®). These drugs selectively block specific inflammatory pathways (IL-4, IL-13) and can dramatically improve quality of life. They are prescribed at specialized centers.
Emollients and dermocosmetics with bioactive ingredients
The foundation of all eczema care is emollients — moisturizing products that protect and restore the skin barrier. Regular moisturizing has been proven to reduce flare frequency and can lower corticosteroid consumption. But modern dermocosmetics go further: products with CBD (cannabidiol) and betulin offer anti-inflammatory, anti-itch, and barrier-restoring effects — without the risks of immunosuppression.
This is exactly where the patented Betuldiol® complex fits in, combining CBD and betulin in a single formula. CBD inhibits pro-inflammatory cytokines and activates the endocannabinoid system in the skin. Betulin supports skin barrier repair and healing. Together, they offer steroid-sparing care that is safe for long-term and daily use — precisely where corticosteroids should only be used in courses.
Why you should never stop corticosteroids abruptly
We cannot emphasize this rule enough: if you've been using corticosteroids for more than two to three weeks, never stop them from one day to the next.
Abrupt discontinuation after long-term use can lead to a dramatic rebound effect — or a full-blown withdrawal syndrome (TSW). The correct approach is tapering — gradual reduction:
- Reduce product potency — step down from Class III to Class II, then to Class I.
- Reduce frequency — from daily application to every other day, then twice weekly.
- Introduce replacement care — simultaneously with tapering, begin regular emollients and potentially a non-steroidal anti-inflammatory product.
- Consult your doctor — ideally, carry out the entire process under a dermatologist's supervision.
Balance: corticosteroids as part, not all, of the treatment
Modern dermatology is heading in a clear direction: corticosteroids remain indispensable for quickly managing acute flares, but the maintenance phase should be non-steroidal whenever possible.
Updated European guidelines (2025) recommend an individualized approach: corticosteroids as first-line for acute conditions, complemented by proactive therapy and emollients, with non-steroidal alternatives (TCI, PDE4 inhibitors, JAK inhibitors) for long-term control — especially on sensitive areas.
This approach is exactly in line with Epiderma's philosophy: we offer steroid-sparing care for the maintenance phase. The product range with the Betuldiol® complex is designed to complement — not replace — medical care. It provides skin barrier support for the time when corticosteroids are no longer needed, but the skin still needs active protection.
Frequently asked questions
Are corticosteroids dangerous?
No, not when used correctly. With short-term use at the right potency and in the right location, corticosteroids are safe and effective. Problems occur with long-term, too-frequent, or too-potent use — especially on the face and in skin folds. Undertreated eczema can be worse for the skin than properly managed corticosteroid treatment.
How long can I use corticosteroids?
It depends on the product's potency and the application site. General rule: mild corticosteroids (Class I–II) on the body for 2–4 weeks, strong corticosteroids (Class III–IV) for a maximum of 14–20 days. On the face and in skin folds, only mild products, short-term. After managing a flare, switch to maintenance care. Always follow your doctor's instructions.
Can I use corticosteroids on my face?
Yes, but only mild products (Class I) and short-term. Facial skin is thin, and absorption is up to 7 times higher than on the body. For longer-term management of facial eczema, non-steroidal alternatives are more suitable — calcineurin inhibitors (Protopic, Elidel) or dermocosmetics with anti-inflammatory properties.
What is a steroid-sparing approach?
Steroid-sparing is a strategy that minimizes corticosteroid use while maintaining eczema control. It includes proactive therapy (corticosteroids just twice weekly), transitioning to non-steroidal products for maintenance, consistent use of emollients, and dermocosmetics with bioactive ingredients.
Can CBD replace corticosteroids?
CBD is not a replacement for corticosteroids during an acute flare — it doesn't have the same strength of anti-inflammatory effect. But as part of a steroid-sparing strategy — for the maintenance phase, skin barrier support, and itch relief — CBD has its place. The Betuldiol® complex combines CBD's anti-inflammatory effects with betulin's barrier-restoring properties, offering safe daily care where corticosteroids should only be used in courses.
Should I be afraid of corticosteroids?
No. But you should treat them with respect — just as you would any effective medication. Use them according to your doctor's recommendations, at the right potency, in the right location, and for the right duration. And have a strategy ready for when you discontinue them — emollients, non-steroidal products, and skin barrier support.
Scientific sources
- Gabros S, Nessel TA, Zito PM. Topical Corticosteroids. StatPearls, updated April 2025. ncbi.nlm.nih.gov/books/NBK532940
- Stacey SK, McEleney M. Topical Corticosteroids: Choice and Application. Am Fam Physician, 2021; 103(6):337-343. aafp.org
- National Eczema Society UK. Topical Steroids Factsheet. 2023. eczema.org
- National Eczema Association. Topical Steroids and Nonsteroid Topicals for Eczema. Updated April 2025. nationaleczema.org
- National Eczema Society UK. Topical Calcineurin Inhibitors. 2025. eczema.org
- European Atopic Eczema Guidelines Update, 2025. dermatologyadvisor.com
- Devasenapathy N et al. Topical anti-inflammatory treatments for eczema: network meta-analysis. Cochrane Database Syst Rev, 2024; 8:CD015064. PubMed:39105474
- Shobnam N et al. Topical Steroid Withdrawal is a Targetable Excess of Mitochondrial NAD+. J Invest Dermatol, 2025. doi:10.1016/j.jid.2024.11.026
This article is for educational purposes and does not replace a medical consultation. Always follow your dermatologist's instructions. Epiderma products are not medicines and are not intended to treat, prevent, or diagnose diseases.